RE: Shares29 Apr 2026 22:55
MedPal AI (LSE:MPAL) has completed the purchase of the pharmacy operations and assets linked to Remedi Solutions’ Runcorn facility through its subsidiary MedPal Limited, in a deal worth £310,000. The acquisition adds a second NHS-registered dispensing hub to the group’s footprint. The Runcorn site previously handled around 1 million prescriptions per year, representing approximately £10 million in annual revenue, and will now operate from newly leased premises within a reorganised group structure under a new holding company, New Performance Health.
The transaction, classified as a related-party deal due to CEO Jason Drummond’s involvement in securing the original rights, strengthens MedPal’s position in specialist pharmacy services for care homes while significantly increasing its dispensing capacity. By replicating its patient reactivation model successfully deployed at its Swaffham hub, the company aims to scale volumes toward a monthly run rate of 80,000 items—seen as the level required to achieve EBITDA breakeven at the pharmacy level and support the wider economics of its digital health platform.